Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 43.2063
- Book/Share 64.2129
- PB 6.8841
- Debt/Equity 0.1
- CurrentRatio 2.6456
- ROIC -0.128
- MktCap 113517113850.0
- FreeCF/Share -4.8968
- PFCF -90.2362
- PE -114.8373
- Debt/Assets 0.0721
- DivYield 0
- ROE -0.0625
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VRTX | Wolfe Research | Outperform | Peer Perform | -- | -- | May 7, 2025 |
| Downgrade | VRTX | Leerink Partners | Outperform | Market Perform | -- | $503 | May 6, 2025 |
| Resumed | VRTX | Cantor Fitzgerald | -- | Overweight | -- | $535 | April 22, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | $408 | $424 | Feb. 12, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | -- | -- | Feb. 11, 2025 |
| Downgrade | VRTX | Wells Fargo | Overweight | Equal Weight | -- | $460 | Jan. 30, 2025 |
| Reiterated | VRTX | H.C. Wainwright | -- | Buy | $600 | $535 | Dec. 20, 2024 |
| Downgrade | VRTX | Oppenheimer | Outperform | Perform | -- | -- | Dec. 19, 2024 |
| Upgrade | VRTX | Jefferies | Hold | Buy | $500 | $550 | Dec. 9, 2024 |
| Initiation | VRTX | Scotiabank | -- | Sector Perform | -- | -- | Oct. 16, 2024 |
News
Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Call Participants Will Pickering - Bernstein Will Pickering All right. Well, I think we can get started.
Read More
3 Top Growth Stocks to Buy in the Second Half of 2025
Published: May 26, 2025 by: The Motley Fool
Sentiment: Positive
Believe it or not, but we're not far away from being halfway through the year. Time flies when you're having fun -- and when you're not having fun, too.
Read More
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Vertex's CF leadership, patent life, and addressable market, while Casgevy and Journavx add new growth avenues. VRTX valuation is justified by stable CF cash flows, a strong balance sheet, proven management, and a diversified pipeline with multiple near-term catalysts.
Read More
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft
Published: May 09, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top names to watch for the second half.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Read More
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
Read More
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets.
Read More
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
Published: May 06, 2025 by: Benzinga
Sentiment: Negative
On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.
Read More
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
Read More
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.
Published: May 06, 2025 by: Barrons
Sentiment: Negative
The company discloses narrower-than-expected access to its new painkiller.
Read More
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
Published: May 06, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following their two-day meeting. The Dow Jones Industrial Average, S&P 500, and Nasdaq all fell.
Read More
2 Pharma Stocks Staging Big Post-Earnings Moves
Published: May 06, 2025 by: Schaeffers Research
Sentiment: Neutral
Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.
Read More
Why Vertex Pharmaceuticals Stock Is Sinking Today
Published: May 06, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Vertex Pharmaceuticals (VRTX -11.69%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday.
Read More
Rising Costs Weigh on Vertex Q1 Earnings
Published: May 06, 2025 by: The Motley Fool
Sentiment: Neutral
Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report.
Read More
Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward.
Read More
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Published: April 30, 2025 by: CNBC Television
Sentiment: Neutral
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!
Read More
What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Getting dizzy from the stock market's gyrations? Join the club.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Read More
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right
Published: April 22, 2025 by: The Motley Fool
Sentiment: Negative
President Trump isn't a fan of Fed Chairman Jerome Powell, despite nominating Powell to replace Janet Yellen in 2017. Trump recently called Powell a "major loser" on a social media post and demanded that he lower interest rates immediately.
Read More
Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike
Published: April 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch in this volatile markets.
Read More
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Read More
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.
Published: April 04, 2025 by: The Motley Fool
Sentiment: Neutral
Which group of individuals is in the best position to spot early warning signs of economic trouble? There's a good case to be made for corporate chief financial officers (CFOs).
Read More
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.
Read More
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Dr. Reshma Kewalramani FASN, M.D.
- Employees 6100